A New Approach to Treating Chronic and Acute Inflammation
Listen to the LFA podcast with Dr. Posada describing Resolve’s phase 2 SLE study
Our Science
Our science addresses a fundamental mechanism of inflammation that occurs in both chronic and acute inflammatory disease processes.
Pathogenic cell-free RNA is produced from different sources depending on the given disease process in amounts and molecular forms that overwhelm the ability of endogenous RNase to remove the RNA. Our technology platform is comprised of drug molecules that remove pathogenic nucleic acids from the plasma compartment thereby eliminating inflammation at its source.
We have demonstrated that this approach improves chronic inflammation in autoimmune diseases such as Sjogren’s syndrome and Systemic lupus Erythematosus (SLE). Chronic inflammation driven by SARS-CoV-2 viral RNA has also responded well to removal of the cell-free RNA.
Several other acute inflammatory diseases are driven by cell-free RNA and respond to RNase in pre-clinical animal models. Some key examples are:
- Ischemia/reperfusion injury associated with stent placement and coronary artery reperfusion in STEMI
- Immune response related secondary brain injury in subarachnoid hemorrhage
- Venous thrombosis
